Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is Selank?
Selank (TBCK, registration number LS-001855 in Russia) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analogue of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from immunoglobulin G that has both immune-modulating and anxiolytic properties.
Selank adds a Pro-Gly-Pro extension to the tuftsin sequence that stabilizes the molecule from enzymatic degradation, extending its effective half-life in the body. This modification was key to making the peptide clinically usable via intranasal administration.
Unlike most research peptides that originate from the West or East Asia, Selank has an unusually robust regulatory history — it is approved as a drug in Russia and Ukraine for generalized anxiety disorder and as a nootropic, backed by controlled clinical trials conducted through the Soviet and post-Soviet pharmaceutical development system.
Mechanism of Action
Selank operates through multiple overlapping neurochemical pathways:
- GABA-A modulation: Selank positively modulates GABA-A receptors — the same receptors targeted by benzodiazepines — but with a fundamentally different binding profile. Unlike benzodiazepines which are direct positive allosteric modulators producing strong sedation and dependence, Selank's GABA-A interaction is more subtle and does not produce sedation, cognitive impairment, or the physical dependence associated with classical anxiolytics.
- BDNF upregulation: Increases brain-derived neurotrophic factor expression in the brain — the key neurotrophin for synaptic plasticity, learning, memory consolidation, and neuronal survival. This is the mechanism underlying its memory-enhancing and neuroprotective effects.
- Serotonin and dopamine modulation: Affects serotonergic and dopaminergic metabolism, contributing to mood regulation without the receptor-level changes that cause dependence.
- Enkephalin degradation inhibition: Inhibits the enzyme that breaks down enkephalins (endogenous opioids), increasing endorphin activity — likely contributing to its anxiolytic effect and slight mood elevation.
- Immune modulation: Via its tuftsin heritage, Selank modulates macrophage activity and cytokine production — an immune effect that may overlap with its stress-response effects.
The "Clean Anxiolytic" Profile
The most clinically relevant aspect of Selank's pharmacology is what it does not do compared to classical anxiety treatments:
- No sedation: Unlike benzodiazepines, antihistamines, and most anxiolytics, Selank does not cause drowsiness or psychomotor impairment. Users describe calm alertness.
- No cognitive impairment: Benzodiazepines impair memory formation and cognitive performance. Selank maintains or improves cognitive performance while reducing anxiety.
- No physical dependence: The GABA-A modulation is qualitatively different from benzodiazepines — Russian regulatory approval did not require dependence scheduling.
- No rebound anxiety: Cessation does not produce rebound anxiety or withdrawal symptoms in the clinical data available.
- No tolerance acceleration: Users report sustained effectiveness without the rapid tolerance development characteristic of benzodiazepines.
The Russian clinical trial data, while real, was conducted within a regulatory system with different standards than FDA or EMA trials. Independent Western replication of Selank's clinical efficacy is limited. The pharmacological mechanisms are well-studied, but the evidence quality by Western regulatory standards would be considered moderate rather than strong. This does not mean Selank doesn't work — users and Russian clinical data suggest it does — but the evidence hierarchy is important context.
Russian Regulatory Status
Selank is registered as a pharmaceutical drug in Russia (LS-001855) approved for:
- Generalized anxiety disorder
- Neurasthenia (stress-related fatigue)
- As a cognitive enhancer/nootropic in appropriate clinical contexts
It is not approved by the FDA, EMA, or CDSCO (India's drug regulator). Outside Russia and Ukraine, it is available as a research compound or supplement depending on jurisdiction.
Nasal Administration: Why Intranasal?
Peptides as a class are poorly bioavailable orally — digestive enzymes break down peptide bonds before the molecule can reach systemic circulation. Injections bypass this but require needles. Intranasal delivery offers a third pathway: the nasal mucosa is highly vascularized, and small molecules (and some peptides) can be absorbed directly into the bloodstream and, via the olfactory nerve pathway, can reach the brain with less systemic dilution.
For Selank specifically, intranasal delivery achieves meaningful CNS concentrations without injection. The olfactory pathway allows direct nose-to-brain transport that bypasses the blood-brain barrier for a portion of the dose — this is a genuine pharmacological advantage for peptides targeting CNS effects.
Selank vs Semax Comparison
| Property | Selank | Semax |
|---|---|---|
| Primary effect | Anxiolytic, calming, memory consolidation | Cognitive activation, focus, motivation |
| Mechanism | GABA-A modulation, BDNF upregulation, enkephalin | BDNF + NGF upregulation, dopaminergic/serotonergic |
| Subjective effect | "Calm clarity" — reduced anxiety without sedation | "Cognitive caffeine" — sharper focus, more alert |
| Administration | Nasal spray | Nasal spray |
| Best time to use | As needed for anxiety, or before stressful situations; some use in evenings | Morning or before cognitively demanding work |
| Regulatory status | Approved in Russia for anxiety/nootropic | Approved in Russia/Ukraine as nootropic |
| India availability | Imported research compound — unregulated | Imported research compound — unregulated |
| Complementary? | Yes — often described as yin-yang pair, used together or at different times of day | |
Dosing Protocol
Standard Selank dosing as used in Russian clinical context and widely reported in nootropic communities:
- Dose per administration: 200-500mcg intranasally (approximately 2-5 drops of standard 0.15% concentration solution)
- Frequency: 2-3 times daily as needed, or specifically before anxiety-provoking situations
- Administration: 2-3 drops per nostril; tilt head slightly back to allow solution to contact nasal mucosa
- Onset: Effects typically noticed within 15-30 minutes
- Duration: 4-6 hours per administration
- Cycling: Some users take daily for 2-4 week periods with breaks; others use situationally as needed
Sourcing and Quality Considerations
Selank is primarily sourced from Russian and Eastern European suppliers, as it originated and is manufactured there. Quality verification is critical — the compound must be handled properly to maintain integrity, and not all suppliers provide reliable peptide content. When available, certificates of analysis from third-party laboratories should confirm ≥98% purity and correct molecular weight.
Frequently Asked Questions
Selank is primarily used as a "clean" anxiolytic — reducing anxiety without sedation, dependence, or cognitive impairment. It is also used to improve cognitive function under stress, enhance memory consolidation, and improve mood stability. The combination of anxiety reduction + maintained (or improved) cognitive performance makes it distinct from most anxiolytics.
Choose Selank primarily for anxiety reduction and stress resilience. Choose Semax primarily for cognitive enhancement, focus, and activation. They have complementary profiles — Selank is calming, Semax is stimulating. Many users use both: Semax in the morning for cognitive performance, Selank as needed for anxiety management or in evenings for calmer cognition.
Selank is not scheduled under India's Drugs and Cosmetics Act or NDPS Act. It is not approved as a medicine in India. It exists in an unregulated gray area — available as an imported research compound without specific legal prohibition, but not legal to sell as a therapeutic product. Regulations can change.
Apply 2-3 drops per nostril from the nasal spray bottle. Tilt head slightly back to allow the solution to contact the nasal mucosa fully. Standard concentration is 0.15% (150mcg/mL), so 2 drops per nostril = approximately 200mcg per dose. Onset is typically 15-30 minutes. Use 2-3 times daily as needed or per the indicated protocol.
Clinical data from Russian trials did not show physical dependence or withdrawal symptoms on cessation. Unlike benzodiazepines, Selank's GABA-A modulation is not the type that causes receptor downregulation and rebound anxiety. This does not mean zero risk — psychological habituation is always possible with anxiolytic compounds — but the pharmacological dependence risk appears low based on available data.